Osilodrostat

Last Updated: 02/24/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 143 publications

Efficacy and safety of osilodrostat for the treatment of Cushing's syndrome

Efficacy and safety of osilodrostat for the treatment of Cushing's syndrome

Journal: Zhonghua nei ke za zhi

Published: January 08, 2026

Osilodrostat for Bilateral Adrenal Hypercortisolism in Primary Aldosteronism.

Osilodrostat for Bilateral Adrenal Hypercortisolism in Primary Aldosteronism.

Journal: The New England journal of medicine

Published: November 26, 2025

Delirium Induced by Rapid Titration of Osilodrostat in a Patient With Cushing's Disease: A Case Report.

Delirium Induced by Rapid Titration of Osilodrostat in a Patient With Cushing's Disease: A Case Report.

Journal: Cureus

Published: November 11, 2025

A case of prolonged adrenal insufficiency following osilodrostat discontinuation with a review of the literature.

A case of prolonged adrenal insufficiency following osilodrostat discontinuation with a review of the literature.

Journal: Endocrine journal

Published: October 26, 2025

Controlling cortisol excess and comorbidities in Cushing's syndrome with osilodrostat.

Controlling cortisol excess and comorbidities in Cushing's syndrome with osilodrostat.

Journal: Pituitary

Published: October 13, 2025

The effect of hypercortisolism treatment on dyslipidemia in Cushing syndrome: systematic review and meta-analysis.

The effect of hypercortisolism treatment on dyslipidemia in Cushing syndrome: systematic review and meta-analysis.

Journal: The Journal of clinical endocrinology and metabolism

Published: September 26, 2025

Real-World Data on the Efficacy and Safety of Osilodrostat in Patients with Cushing's Disease in Spain.

Real-World Data on the Efficacy and Safety of Osilodrostat in Patients with Cushing's Disease in Spain.

Journal: Journal of clinical medicine

Published: September 23, 2025

Case Report: Ectopic Cushing's syndrome caused by a pancreatic neuroendocrine tumor managed through dual steroidogenesis inhibition and endoscopic ultrasound-guided ethanol ablation.

Case Report: Ectopic Cushing's syndrome caused by a pancreatic neuroendocrine tumor managed through dual steroidogenesis inhibition and endoscopic ultrasound-guided ethanol ablation.

Journal: Frontiers in endocrinology

Published: September 06, 2025

Blood steroid hormone profile and clinical outcomes following switching from metyrapone to osilodrostat in patients with Cushing disease.

Blood steroid hormone profile and clinical outcomes following switching from metyrapone to osilodrostat in patients with Cushing disease.

Journal: Endocrine journal

Published: August 31, 2025

Clinical management of ectopic Cushing Syndrome in neuroendocrine neoplasms: a national survey.

Clinical management of ectopic Cushing Syndrome in neuroendocrine neoplasms: a national survey.

Journal: Frontiers in endocrinology

Published: August 22, 2025

Adverse Event Profile Differences Between Metyrapone and Osilodrostat: A Pharmacovigilance Study of the FDA Adverse Event Reporting System.

Adverse Event Profile Differences Between Metyrapone and Osilodrostat: A Pharmacovigilance Study of the FDA Adverse Event Reporting System.

Journal: Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme

Published: August 18, 2025

Osilodrostat-associated Adrenal Gland Shrinkage: a Case Series of Patients with ACTH-Dependent Cushing's Syndrome.

Osilodrostat-associated Adrenal Gland Shrinkage: a Case Series of Patients with ACTH-Dependent Cushing's Syndrome.

Journal: The Journal of clinical endocrinology and metabolism

Published: August 17, 2025

Showing 1-12 of 143

Last Updated: 02/24/2026